- Details
- Jaime Landman presented the development and initial clinical experience of the Monarch PCNL, a novel endoscopic robotic platform aimed at improving stone-free rates at the American Urologic Society meeting in 2023. The Monarch PCNL employs aspiration and laser innovations to get better access to stones and improve stone-free rates. Developed by Auris, the Monarch PCNL is a percutaneous access plat...
|
- Details
- Laurence Albiges joins Pedro Barata highlighting the phase 2 KEYNOTE-B61 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). This is an area of unmet need and during the ESMO 2022 meeting, Dr. Albiges presented study data for the first time. KEYNOTE-B61 enroll patients with non-clear cell histology that have never been pre...
|
- Details
- Ralph Clayman converses with Jaime Landman about the controversial practice of biopsying renal masses, a topic that has stirred significant debate within the medical community. Dr. Landman elucidates the merits of Biopsy Informed Active Surveillance (BIAS), a departure from the existing renal mass guidelines that he argues are largely culture-based rather than data-driven. Dr. Landman highlights t...
|
- Details
- Medical Oncologist and member of the scientific committee of the upcoming European International Kidney Cancer Symposium, Samra Turajlic joins Rana McKay to discuss the upcoming IKCS meeting being held April 22nd through the 24th in Antwerpen, Belgium. The program will consist of Award Lectures in Urology and Oncology, Basic Science in renal cell carcinoma (RCC), Biomarkers in RCC, Diagnostics, an...
|
- Details
- In this conversation, Roger Dmochowski, David Chaikin, & Vijay Goli discuss the United States (US) Federal Drug Administration (FDA) cleared single-use disposable UroViu cystoscopic platform and share their experience with the device as well as the economic implications for Urology and UroGynecology practices. If you are interested in a demo, you can reach the UroViu Corporation via their website:...
|
- Details
- Sam Chang and Ryan Hsi, discuss percutaneous techniques and evaluation for upper tract tumors. Dr. Hsi begins this conversation with a background on antegrade approaches. He discusses the goals of these antegrade approaches to be obtaining tissues and cytologies, while also ablating, resecting, and treating the visible tumor. He also goes on to discuss his approach to using antegrade techniques, w...
|
- Details
- Jaime Landman speaks with Thomas Tailly, who delves into his manuscript titled "Reusable, Single-Use or Both: A Cost-Efficiency Analysis of Flexible Ureterorenoscopes After 983 Cases," which explores the financial viability of reusable vs. single-use scopes in ureteroscopy. Dr. Tailly and his team have created an adaptable formula to determine cost-efficiency based on factors such as repair costs,...
|
- Details
- Dena Battle from KCCure, a kidney cancer patient advocacy organization, joins Jaime Landman and Monty Pal to dispel common myths regarding the diagnosis and treatment of kidney cancer being observed in patient communities and to speak about what is driving this misinformation. Among the factors are evolving data, practice-changing data since first diagnoses, the lack of consensus where there isn’t...
|
- Details
- There is a need for more realistic surgical training and the need to train outside of the patient for fellows and residents. The traditional approach of on-patient training is evolving to a great reliance on simulators with more complex platforms. The best patient outcomes from minimally invasive partial nephrectomy, for incidental renal masses, done through either laparoscopy or the robotic platf...
|
- Details
- Principal investigator Tian Zhang joins Alicia Morgans to discuss the recent progress of the currently enrolling PDIGREE (Alliance A031704) trial. PDIGREE: An Adaptive Phase III Trial of PD-Inhibitor Nivolumab and Ipilimumab with VEGF TKI Cabozantinib in Metastatic Untreated Renal Cell Cancer (Alliance A031704) has been open since May of 2019 and now has nearly 300 patients enrolled, many of whom...
|
